Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409783 | 1.00 | AKR1B1 (0.43) | AKR1B1GAPDH | |
| SCHEMBL1044688 | 1.00 | AKR1B1 (0.43) | AKR1B1GAPDH | |
| SCHEMBL130943 | 1.00 | AKR1B1 (0.43) | AKR1B1GAPDH | |
| SCHEMBL3425314 | 1.00 | AKR1B1 (0.43) | AKR1B1GAPDH | |
| SCHEMBL5987889 | 1.00 | AKR1B1 (0.43) | AKR1B1GAPDH | |
| SCHEMBL29409479 | 0.97 | AKR1B1 (0.42) | AKR1B1GAPDH | |
| Ammonia Solution, Strong SCHEMBL28822860 | 0.97 | AKR1B1 (0.42) | AKR1B1GAPDH | |
| SCHEMBL30664650 | 0.97 | AKR1B1 (0.42) | AKR1B1GAPDH | |
| Alcohol SCHEMBL28228654 | 0.93 | AKR1B1 (0.44) | AKR1B1GAPDH | |
| Phosphoric Acid SCHEMBL5790794 | 0.91 | AKR1B1 (0.37) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 496 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025083657-A1 | LIPID COMPOUND AND COMPOSITION FOR TISSUE-SPECIFIC DELIVERY OF ACTIVE SUBSTANCE | 한국생명공학연구원 | 2025-04-24 | — | — | WO | claimed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | claimed |
| WO-2018187574-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2018-10-11 | — | — | WO | claimed |
| CN-108136040-A | For the multiple ligand reagent of drug delivery | 阿克丘勒斯治疗公司 | 2018-06-08 | — | — | CN | claimed |
| EP-3328439-A1 | MULTILIGAND AGENT FOR DRUG DELIVERY | Arcturus Therapeutics, Inc. (US) | 2018-06-06 | — | — | EP | claimed |
| WO-2018006063-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2018-01-04 | — | — | WO | claimed |
| CN-105805426-B | Pipeline runs through device | 上海火克新材料有限公司 | 2017-10-27 | — | — | CN | claimed |
| WO-2017023817-A1 | MULTILIGAND AGENT FOR DRUG DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2017-02-09 | — | — | WO | claimed |
| EP-3076781-A1 | FLOWER FOAM | Spicer Designs Limited (GB) | 2016-10-12 | — | — | EP | claimed |
| CN-105805426-A | Pipeline penetration device | 上海火克新材料有限公司 | 2016-07-27 | — | — | CN | claimed |
| WO-2015082898-A1 | FLOWER FOAM | SPICER DESIGNS LIMITED (GB) | 2015-06-11 | — | — | WO | claimed |
| US-7538092-B2 | Pharmaceutically active oligosaccharide conjugates | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2009-05-26 | — | — | US | claimed |
| EP-1549350-B1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | FRESENIUS KABI DE GMBH (DE) | 2008-09-24 | — | — | EP | claimed |
| US-20060100163-A1 | Pharmaceutically active oligosaccharide conjugates | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2006-05-11 | — | — | US | claimed |
| US-20050267169-A1 | Watersoluble prodrugs of propofol | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2005-12-01 | — | — | US | claimed |
| EP-1554242-A1 | WATERSOLUBLE PRODRUGS OF PROPOFOL | Fresenius Kabi Deutschland GmbH (DE) | 2005-07-20 | — | — | EP | claimed |
| EP-1549350-A1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | Fresenius Kabi Deutschland GmbH (DE) | 2005-07-06 | — | — | EP | claimed |
| WO-2004032971-A1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2004-04-22 | — | — | WO | claimed |
| WO-2004033424-A1 | WATERSOLUBLE PRODRUGS OF PROPOFOL | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2004-04-22 | — | — | WO | claimed |
| EP-4235163-B1 | SENSOR INCLUDING A REFERENCE ELECTRODE | SYSMEX CORP (JP) | 2026-03-11 | — | — | EP | disclosed |
| US-12569570-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260053912-A1 | STEROLS AS NOVEL IMMUNOMODULATORY AGENTS AND THEIR USE AS VACCINE ADJUVANTS | UNITED STATES GOVERNMENT | 2026-02-26 | — | — | US | disclosed |
| EP-4700124-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Alnylam Pharmaceuticals, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4686760-A1 | SIALYLTRANSFERASES FOR THE SYNTHESIS OF SIALYLATED GLYCANS, GLYCOCONJUGATES AND GLYCOPROTEINS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-02-04 | — | — | EP | disclosed |
| US-12478671-B2 | Sterols as novel immunomodulatory agents and their use as vaccine adjuvants | OHIO STATE INNOVATION FOUNDATION (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250338808-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | BOYCE THOMPSON INSTITUTE FOR PLANT RES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12429448-B2 | Reference electrode, electrode, and sensor including these | SYSMEX CORPORATION (JP) | 2025-09-30 | — | — | US | disclosed |
| US-20250295747-A1 | RECOMBINANT ATTENUATED SALMONELLA VACCINES (RASVS) AGAINST INFECTIONS BY AVIAN PATHOGENIC ESCHERICHIA COLI (APEC) | HUVEPHARMA INC. (US) | 2025-09-25 | — | — | US | disclosed |
| US-12382888-B2 | Compositions and methods for modulating immunity in plants | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4594530-A1 | NUCLEIC ACID SEQUENCING COMPONENTS INCLUDING A GLYCOLIPID BI-LAYER | Illumina, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12377113-B2 | Glycan therapeutic compositions and related methods thereof | DSM NUTRITIONAL PRODUCTS, LLC (US) | 2025-08-05 | — | — | US | disclosed |
| EP-4590429-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | Donaldson Company, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4590428-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES | Donaldson Company, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250236685-A1 | DEGRADABLE POLYMERS | THE TRUSTEES OF BOSTON COLLEGE | 2025-07-24 | — | — | US | disclosed |
| US-20250236636-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | VERVE THERAPEUTICS, INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250228953-A1 | INTRACELLULAR TARGETING OF OLIGONUCLEOTIDES | ENTRADA THERAPEUTICS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-20250179108-A1 | UTILITY OF NEMATODE SMALL MOLECULES | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH | 2025-06-05 | — | — | US | disclosed |
| EP-4549531-A1 | ADHESIVE AGENT FOR RESIN, AND LAYERED BODY | Nihon Parkerizing Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| EP-4549433-A1 | HYDROGENATION OF CARBOHYDRATES AND FURFURAL USING HYDROGEN WITH LOW DEUTERIUM CONTENT | BASF SE (DE) | 2025-05-07 | — | — | EP | disclosed |
| WO-2025083657-A1 | LIPID COMPOUND AND COMPOSITION FOR TISSUE-SPECIFIC DELIVERY OF ACTIVE SUBSTANCE | 한국생명공학연구원 | 2025-04-24 | — | — | WO | disclosed |
| US-12274753-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-12275973-B2 | Enzymatic method for preparation of CMP-Neu5Ac | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) | 2025-04-15 | — | — | US | disclosed |
| US-12264175-B2 | Compositions and methods for capping RNAS | VERVE THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20250084409-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | VERVE THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| US-20250075208-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2025-03-06 | — | — | US | disclosed |
| EP-4486355-A2 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | Verve Therapeutics, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| US-12180246-B2 | Utility of nematode small molecules | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-12-31 | — | — | US | disclosed |
| US-12173288-B2 | Oligonucleotide-ligand conjugates and process for their preparation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240352497-A1 | ENZYMATIC METHOD FOR PREPARATION OF CMP-NEU5AC | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2024-10-24 | — | — | US | disclosed |
| US-20240335551-A1 | FUNCTIONAL MOIETIES AND THEIR USES AND SYNTHETIC PREPARATION | OLIX US, INC. | 2024-10-10 | — | — | US | disclosed |
| US-20240315186-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. | 2024-09-26 | — | — | US | disclosed |
| US-20240316212-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-12090168-B2 | Glucose glycans for treating urea cycle disorders | DSM NUTRITIONAL PRODUCTS, LLC (US) | 2024-09-17 | — | — | US | disclosed |
| US-12059468-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| CN-118348084-A | Reference electrode, and sensor provided with both | 希森美康株式会社 | 2024-07-16 | — | — | CN | disclosed |
| US-20240189797-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| US-20240190913-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | DONALDSON COMPANY, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240190912-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-13 | — | — | US | disclosed |
| EP-4380576-A2 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | Verve Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-3703705-B1 | GLUCOSE-CONTAINING GLYCAN PREPARATIONS FOR USE IN THE TREATMENT OF HYPERAMMONAEMIA | DSM NUTRITIONAL PRODUCTS LLC (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024091521-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES | DONALDSON COMPANY, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024091527-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | DONALDSON COMPANY, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024091520-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | DONALDSON COMPANY, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20240132956-A1 | NUCLEIC ACID SEQUENCING COMPONENTS INCLUDING A GLYCOLIPID BI-LAYER | ILLUMINA, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240131166-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240124911-A1 | ENZYMATIC METHOD FOR PREPARATION OF GDP-FUCOSE | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2024-04-18 | — | — | US | disclosed |
| US-20240108642-A1 | GLYCAN THERAPEUTIC COMPOSITIONS AND RELATED METHODS THEREOF | DSM NUTRITIONAL PRODUCTS, LLC | 2024-04-04 | — | — | US | disclosed |
| WO-2024073506-A1 | NUCLEIC ACID SEQUENCING COMPONENTS INCLUDING A GLYCOLIPID BI-LAYER | ILLUMINA, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240100169-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| EP-4341269-A1 | FUNCTIONAL MOIETIES AND THEIR USES AND SYNTHETIC PREPARATION | Olix US, Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4321177-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-11884961-B2 | DNA-glycan conjugates and methods of use | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-11883422-B2 | Glycan therapeutic compositions and related methods thereof | DSM NUTRITIONAL PRODUCTS, LLC (US) | 2024-01-30 | — | — | US | disclosed |
| US-20240018177-A1 | UTILITY OF NEMATODE SMALL MOLECULES | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH | 2024-01-18 | — | — | US | disclosed |
| EP-4295840-A2 | GLYCAN POLYMERS AND RELATED METHODS THEREOF | DSM Nutritional Products, LLC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11849688-B2 | Compositions and methods for modulating immunity in plants | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2023-12-26 | — | — | US | disclosed |
| EP-4103730-B1 | ENZYMATIC METHOD FOR PREPARATION OF CMP-NEU5AC | MAX PLANCK GESELLSCHAFT (DE) | 2023-11-22 | — | — | EP | disclosed |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-11795486-B2 | Enzymatic method for preparation of GDP-fucose | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-10-24 | — | — | US | disclosed |
| US-20230331763-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | VERVE THERAPEUTICS, INC. | 2023-10-19 | — | — | US | disclosed |
| EP-3551194-B1 | GLYCAN POLYMERS AND RELATED METHODS THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-10-18 | — | — | EP | disclosed |
| EP-3784792-B9 | ENZYMATIC METHOD FOR PREPARATION OF GDP-FUCOSE | MAX PLANCK GESELLSCHAFT (DE) | 2023-10-04 | — | — | EP | disclosed |
| US-11772063-B2 | Method and device for producing saccharides and saccharide arrays | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-10-03 | — | — | US | disclosed |
| US-11767546-B2 | Enzymatic method for preparation of UDP-GlcNAc | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-09-26 | — | — | US | disclosed |
| CN-116745430-A | Production of oligosaccharides comprising LN3 as core structure in host cells | 因比奥斯公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2023167880-A2 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | VERVE THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230273142-A1 | REFERENCE ELECTRODE, ELECTRODE, AND SENSOR INCLUDING THESE | SYSMEX CORPORATION (JP) | 2023-08-31 | — | — | US | disclosed |
| EP-4235163-A1 | REFERENCE ELECTRODE, ELECTRODE, AND SENSOR INCLUDING THESE | SYSMEX CORPORATION (JP) | 2023-08-30 | — | — | EP | disclosed |
| US-11739358-B2 | Enzymatic method for preparation of UDP-galactose | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-08-29 | — | — | US | disclosed |
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| EP-4223299-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-4208549-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | Verve Therapeutics, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11697692-B2 | Methods of producing glycan polymers | DSM NUTRITIONAL PRODUCTS, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| EP-3705125-B1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116270718-A | Glycan therapeutic and methods of treatment | DSM营养产品有限责任公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-3897958-B1 | METHOD AND DEVICE FOR PRODUCING SACCHARIDES AND SACCHARIDE ARRAYS | MAX PLANCK GESELLSCHAFT (DE) | 2023-06-21 | — | — | EP | disclosed |
| EP-3874056-B1 | ENZYMATIC METHOD FOR PREPARATION OF UDP-GLCNAC | MAX PLANCK GESELLSCHAFT (DE) | 2023-06-14 | — | — | EP | disclosed |
| EP-3874055-B1 | ENZYMATIC METHOD FOR PREPARATION OF UDP-GALACTOSE | MAX PLANCK GESELLSCHAFT (DE) | 2023-06-14 | — | — | EP | disclosed |
| US-11673908-B2 | Utility of nematode small molecules | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2023-06-13 | — | — | US | disclosed |
| CN-116249781-A | Production of biological products containing GlcNAc in cells | 因比奥斯公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-3784792-B1 | ENZYMATIC METHOD FOR PREPARATION OF GDP-FUCOSE | MAX PLANCK GESELLSCHAFT (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-11666653-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| WO-2023092188-A1 | \"COMPOUNDS AND METHODS\ | DemAgtech Pty Ltd (AU) | 2023-06-01 | — | — | WO | disclosed |
| US-11654114-B2 | Oral prolonged drug delivery platforms | EGY-NANO PHARMA, LP (EG) | 2023-05-23 | — | — | US | disclosed |
| WO-2023081893-A1 | INTRACELLULAR TARGETING OF OLIGONUCLEOTIDES | ENTRADA THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20230123695-A1 | GLYCAN COMPOSITIONS AND METHODS OF USE | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230113218-A1 | GLYCAN PREPARATIONS FOR THE TREATMENT OF INFECTION | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2023015223-A9 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| EP-3484483-B1 | GLYCAN COMPOSITIONS AND METHODS OF USE | KALEIDO BIOSCIENCES INC (US) | 2023-03-08 | — | — | EP | disclosed |
| WO-2023015223-A2 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20230024046-A1 | UTILITY OF NEMATODE SMALL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-01-26 | — | — | US | disclosed |
| EP-4114360-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | Verve Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220409650-A1 | COMPOSITIONS AND METHODS FOR ASCAROSIDE MODIFICATION OF MAMMALIAN MICROBIOTA | HOLOCLARA INC (US) | 2022-12-29 | — | — | US | disclosed |
| EP-4103730-A1 | ENZYMATIC METHOD FOR PREPARATION OF CMP-NEU5AC | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-21 | — | — | EP | disclosed |
| US-20220395800-A1 | DEVICE FOR AUTOMATED SYNTHESIS OF OLIGO- AND POLYSACCHARIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2022-12-15 | — | — | US | disclosed |
| US-20220387957-A1 | MICROWAVE-ASSISTED METHOD FOR SYNTHESIS OF OLIGO- AND POLYSACCHARIDES ON SOLID PHASE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-08 | — | — | US | disclosed |
| US-20220389469-A1 | ENZYMATIC METHOD FOR PREPARATION OF UDP-GALATOSE | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2022-12-08 | — | — | US | disclosed |
| US-20220380820-A1 | ENZYMATIC METHOD FOR PREPARATION OF UDP-GLCNAC | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-01 | — | — | US | disclosed |
| WO-2022246195-A1 | FUNCTIONAL MOIETIES AND THEIR USES AND SYNTHETIC PREPARATION | OLIX US, INC. (US) | 2022-11-24 | — | — | WO | disclosed |
| US-20220348914-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2022-11-03 | — | — | US | disclosed |
| EP-4074344-A1 | TARGETING LIPIDS | Arbutus Biopharma Corporation (CA) | 2022-10-19 | — | — | EP | disclosed |
| US-11471479-B2 | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents | EAGLE BIOLOGICS, INC. (US) | 2022-10-18 | — | — | US | disclosed |
| EP-4045180-A1 | DEVICE FOR AUTOMATED SYNTHESIS OF OLIGO- AND POLYSACCHARIDES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-08-24 | — | — | EP | disclosed |
| EP-4045182-A1 | MICROWAVE-ASSISTED METHOD FOR SYNTHESIS OF OLIGO- AND POLYSACCHARIDES ON SOLID PHASE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-08-24 | — | — | EP | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20220248687-A1 | METHOD FOR PROMOTING BACTERIAL CELL WALL DEGRADATION | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2022-08-11 | — | — | US | disclosed |
| EP-4039278-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Alnylam Pharmaceuticals, Inc. (US) | 2022-08-10 | — | — | EP | disclosed |
| US-20220233577-A1 | GLYCAN PREPARATIONS AND METHODS OF USE FOR HYPERAMMONEMIA | KALEIDO BIOSCIENCES, INC. | 2022-07-28 | — | — | US | disclosed |
| US-20220177940-A1 | ENZYMATIC METHOD FOR PREPARATION OF GDP-FUCOSE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-06-09 | — | — | US | disclosed |
| US-20220152210-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220143189-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2022-05-12 | — | — | US | disclosed |
| US-20220127605-A1 | NUCLEIC ACID CONJUGATE | KYOWA KIRIN CO., LTD. (JP) | 2022-04-28 | — | — | US | disclosed |
| US-20220111034-A1 | VIRUS COMPOSITIONS | Université Catholique de Louvain (BE) | 2022-04-14 | — | — | US | disclosed |
| EP-3019200-B1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | ALNYLAM PHARMACEUTICALS INC (US) | 2022-03-23 | — | — | EP | disclosed |
| WO-2022051677-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | VERVE THERAPEUTICS, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20220062849-A1 | METHOD AND DEVICE FOR PRODUCING SACCHARIDES AND SACCHARIDE ARRAYS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-03-03 | — | — | US | disclosed |
| EP-3950926-A1 | METHOD FOR PROMOTING BACTERIAL CELL WALL DEGRADATION | Kabushiki Kaisha Yakult Honsha (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-11236376-B2 | Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides | Glycosyn LLC (US) | 2022-02-01 | — | — | US | disclosed |
| US-11229660-B2 | Glycan therapeutics and method of treating conditions associated with TMAO | KALEIDO BIOSCIENCES, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20220008541-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2022-01-13 | — | — | US | disclosed |
| US-20210401861-A1 | GLYCAN THERAPEUTIC COMPOSITIONS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2021-12-30 | — | — | US | disclosed |
| US-11207416-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| CN-108699558-B | Nucleic acid complexes | 协和麒麟株式会社 | 2021-12-07 | — | — | CN | disclosed |
| EP-3911333-A1 | VIRUS COMPOSITIONS | Université catholique de Louvain (BE) | 2021-11-24 | — | — | EP | disclosed |
| US-20210332406-A1 | SEROTYPE DETERMINATION METHOD | SHIMADZU CORPORATION (JP) | 2021-10-28 | — | — | US | disclosed |
| EP-3897958-A1 | METHOD AND DEVICE FOR PRODUCING SACCHARIDES AND SACCHARIDE ARRAYS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-10-27 | — | — | EP | disclosed |
| EP-3892731-A1 | ENZYMATIC METHOD FOR PREPARATION OF CMP-NEU5AC | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-10-13 | — | — | EP | disclosed |
| EP-3888663-A1 | NUCLEIC ACID COMPLEX | Kyowa Kirin Co., Ltd. (JP) | 2021-10-06 | — | — | EP | disclosed |
| US-20210299261-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2021178725-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. (US) | 2021-09-10 | — | — | WO | disclosed |
| EP-3874056-A1 | ENZYMATIC METHOD FOR PREPARATION OF UDP-GLCNAC | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-09-08 | — | — | EP | disclosed |
| EP-3874055-A1 | ENZYMATIC METHOD FOR PREPARATION OF UDP-GALACTOSE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-09-08 | — | — | EP | disclosed |
| US-11110174-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| CN-113286600-A | Nucleic acid complexes | 协和麒麟株式会社 | 2021-08-20 | — | — | CN | disclosed |
| EP-3862002-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | Kaleido Biosciences, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3862006-A1 | GLYCAN PREPARATIONS FOR THE TREATMENT OF INFECTION | Kaleido Biosciences, Inc. (US) | 2021-08-11 | — | — | EP | disclosed |
| EP-3835306-A1 | MICROWAVE-ASSISTED METHOD FOR SYNTHESIS OF OLIGO- AND POLYSACCHARIDES ON SOLID PHASE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-06-16 | — | — | EP | disclosed |
| EP-3285777-B1 | GLYCAN THERAPEUTICS AND METHODS OF TREATMENT | KALEIDO BIOSCIENCES INC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-20210161942-A1 | GLYCAN COMPOSITIONS AND METHODS OF USE | HERCULES CAPITAL, INC. | 2021-06-03 | — | — | US | disclosed |
| US-11019776-B2 | Compositions and methods for modulating immunity in plants | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210137956-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | HERCULES CAPITAL, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210137964-A1 | GLYCAN COMPOSITIONS AND METHODS OF USE | HERCULES CAPITAL, INC. | 2021-05-13 | — | — | US | disclosed |
| EP-3819382-A1 | ENZYMATIC METHOD FOR PREPARATION OF UDP-GLCNAC | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-05-12 | — | — | EP | disclosed |
| EP-3819381-A1 | ENZYMATIC METHOD FOR PREPARATION OF UDP-GALACTOSE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-05-12 | — | — | EP | disclosed |
| EP-3815778-A1 | DEVICE FOR RAPID AUTOMATED SYNTHESIS OF OLIGO- AND POLYSACCHARIDES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-05-05 | — | — | EP | disclosed |
| US-20210113596-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| US-10973936-B2 | 18F-saccharide-folates | Merck & Cie (CH) | 2021-04-13 | — | — | US | disclosed |
| EP-3784792-A1 | ENZYMATIC METHOD FOR PREPARATION OF GDP-FUCOSE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-03-03 | — | — | EP | disclosed |
| EP-3409780-B1 | NUCLEIC ACID COMPLEX | KYOWA KIRIN CO LTD (JP) | 2021-01-20 | — | — | EP | disclosed |
| US-10894057-B2 | Glycan therapeutic compositions and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-10881676-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| EP-3354282-B1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES INC (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200390798-A1 | GLYCAN POLYMERS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS LTD (IE) | 2020-12-17 | — | — | US | disclosed |
| WO-2020247480-A1 | COMPOSITIONS AND METHODS FOR ASCAROSIDE MODIFICATION OF MAMMALIAN MICROBIOTA | HOLOCLARA, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200354481-A1 | METHODS OF PRODUCING GLYCAN POLYMERS | HERCULES CAPITAL, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20200352980-A1 | GLYCAN PREPARATIONS FOR THE TREATMENT OF INFECTION | HERCULES CAPITAL, INC. | 2020-11-12 | — | — | US | disclosed |
| US-10808246-B2 | Oligonucleotide-ligand conjugates and process for their preparation | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10806791-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| EP-2993182-B1 | IMMUNITY INDUCER FOR SACCHARIDE ANTIGENS | AIST (JP) | 2020-10-14 | — | — | EP | disclosed |
| WO-2020201315-A1 | ENZYMATIC METHOD FOR PREPARATION OF GDP-FUCOSE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-10-08 | — | — | WO | disclosed |
| EP-3719135-A1 | ENZYMATIC METHOD FOR PREPARATION OF GDP-FUCOSE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-10-07 | — | — | EP | disclosed |
| WO-2020196374-A1 | METHOD FOR PROMOTING BACTERIAL CELL WALL DEGRADATION | 株式会社ヤクルト本社 | 2020-10-01 | — | — | WO | disclosed |
| US-20200297853-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2020-09-24 | — | — | US | disclosed |
| EP-3703704-A1 | GLYCAN PREPARATIONS FOR THE TREATMENT OF INFECTION | Kaleido Biosciences, Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3704161-A1 | METHODS OF PRODUCING GLYCAN POLYMERS | Kaleido Biosciences, Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3703705-A2 | GLYCAN PREPARATIONS AND METHODS OF USE FOR HYPERAMMONEMIA | Kaleido Biosciences, Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3705125-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20200262856-A1 | UTILITY OF NEMATODE SMALL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-08-20 | — | — | US | disclosed |
| US-10745700-B2 | Nucleic acid conjugate | KYOWA KIRIN CO., LTD. (JP) | 2020-08-18 | — | — | US | disclosed |
| WO-2020148422-A1 | VIRUS COMPOSITIONS | Université Catholique de Louvain (BE) | 2020-07-23 | — | — | WO | disclosed |
| US-10702542-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| WO-2020127391-A1 | METHOD AND DEVICE FOR PRODUCING SACCHARIDES AND SACCHARIDE ARRAYS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-06-25 | — | — | WO | disclosed |
| US-20200197514-A1 | STEROLS AS NOVEL IMMUNOMODULATORY AGENTS AND THEIR USE AS VACCINE ADJUVANTS | OHIO STATE INNOVATION FOUNDATION | 2020-06-25 | — | — | US | disclosed |
| EP-3670521-A1 | METHOD AND DEVICE FOR PRODUCING SACCHARIDES AND SACCHARIDE ARRAYS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2020-06-24 | — | — | EP | disclosed |
| US-20200163894-A1 | ORAL PROLONGED DRUG DELIVERY PLATFORMS | CNH INDUSTRIAL AMERICA LLC | 2020-05-28 | — | — | US | disclosed |
| EP-3651776-A1 | GLYCAN COMPOSITIONS AND METHODS OF USE | Kaleido Biosciences, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3077360-B1 | CATALYTIC FORMATION OF CARBON MONOXIDE (CO) AND HYDROGEN (H2) FROM BIOMASS | YEDA RES & DEV (IL) | 2020-04-22 | — | — | EP | disclosed |
| EP-3634507-A1 | ORAL PROLONGED DRUG DELIVERY PLATFORMS | EGY-Nano Pharma, LP (EG) | 2020-04-15 | — | — | EP | disclosed |
| US-20200109435-A1 | DNA-GLYCAN CONJUGATES AND METHODS OF USE | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (GSURF) | 2020-04-09 | — | — | US | disclosed |
| EP-3328439-B1 | MULTILIGAND AGENT FOR DRUG DELIVERY | ARCTURUS THERAPEUTICS INC (US) | 2020-04-08 | — | — | EP | disclosed |
| US-20200093851-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| US-20200093845-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2020-03-26 | — | — | US | disclosed |
| US-20200087691-A1 | ALPHA (1,2) FUCOSYLTRANSFERASES SUITABLE FOR USE IN THE PRODUCTION OF FUCOSYLATED OLIGOSACCHARIDES | GINKGO BIOWORKS, INC. | 2020-03-19 | — | — | US | disclosed |
| US-10479813-B2 | Utility of nematode small molecules | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-11-19 | — | — | US | disclosed |
| EP-3563682-A1 | THE UTILITY OF NEMATODE SMALL MOLECULES | California Institute of Technology (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3551194-A1 | GLYCAN POLYMERS AND RELATED METHODS THEREOF | Kaleido Biosciences, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190290675-A1 | GLYCAN POLYMERS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2019-09-26 | — | — | US | disclosed |
| CN-110267663-A | Chitosan polymer and its correlation technique | 卡莱多生物科技有限公司 | 2019-09-20 | — | — | CN | disclosed |
| US-20190255200-A1 | 18F-SACCHARIDE-FOLATES | Merck & Cie (CH) | 2019-08-22 | — | — | US | disclosed |
| US-20190184018-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2019-06-20 | — | — | US | disclosed |
| US-10322195-B2 | 18F-saccharide-folates | Merck & Cie (CH) | 2019-06-18 | — | — | US | disclosed |
| US-10314853-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10307471-B2 | Immunity inducer for saccharide antigens | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2019-06-04 | — | — | US | disclosed |
| US-20190153014-A1 | UTILITY OF NEMATODE SMALL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-05-23 | — | — | US | disclosed |
| EP-3484483-A1 | GLYCAN COMPOSITIONS AND METHODS OF USE | Kaleido Biosciences, Inc. (US) | 2019-05-22 | — | — | EP | disclosed |
| EP-2877574-B1 | ALPHA (1,2) FUCOSYLTRANSFERASES SUITABLE FOR USE IN THE PRODUCTION OF FUCOSYLATED OLIGOSACCHARIDES | Glycosyn LLC (US) | 2019-05-15 | — | — | EP | disclosed |
| US-10273516-B2 | Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides | Glycosyn LLC (US) | 2019-04-30 | — | — | US | disclosed |
| CN-109689067-A | GLYCAN COMPOSITIONS AND METHODS OF USE | 卡莱多生物科技有限公司 | 2019-04-26 | — | — | CN | disclosed |
| US-20190099493-A1 | Targeting Lipids | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-04-04 | — | — | US | disclosed |
| US-20190091249-A1 | GLYCAN THERAPEUTIC COMPOSITIONS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2019-03-28 | — | — | US | disclosed |
| WO-2019040879-A1 | STEROLS AS NOVEL IMMUNOMODULATORY AGENTS AND THEIR USE AS VACCINE ADJUVANTS | OHIO STATE INNOVATION FOUNDATION (US) | 2019-02-28 | — | — | WO | disclosed |
| US-20190055558-A1 | NUCLEIC ACID CONJUGATE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-02-21 | — | — | US | disclosed |
| US-20190053451-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. | 2019-02-21 | — | — | US | disclosed |
| US-10183963-B2 | Utility of nematode small molecules | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-01-22 | — | — | US | disclosed |
| WO-2019014645-A1 | GLYCAN COMPOSITIONS AND METHODS OF USE | KALEIDO BIOSCIENCES, INC. (US) | 2019-01-17 | — | — | WO | disclosed |
| WO-2018226383-A1 | ORAL PROLONGED DRUG DELIVERY PLATFORMS | EGY-NANO PHARMA, LP (EG) | 2018-12-13 | — | — | WO | disclosed |
| WO-2018223014-A1 | DNA-GLYCAN CONJUGATES AND METHODS OF USE | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATON, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
| EP-3409780-A1 | NUCLEIC ACID COMPLEX | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-12-05 | — | — | EP | disclosed |
| US-10136595-B2 | Compositions and methods for modulating immunity in plants | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20180326070-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. | 2018-11-15 | — | — | US | disclosed |
| US-20180303864-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-10-25 | — | — | US | disclosed |
| CN-108699558-A | nucleic acid complexes | 协和发酵麒麟株式会社 | 2018-10-23 | — | — | CN | disclosed |
| WO-2018187574-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2018-10-11 | — | — | WO | disclosed |
| EP-2776382-B1 | 18F-SACCHARIDE-FOLATES | Merck & Cie (CH) | 2018-09-19 | — | — | EP | disclosed |
| US-20180235987-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | HERCULES CAPITAL, INC. | 2018-08-23 | — | — | US | disclosed |
| EP-3354282-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | Kaleido Biosciences, Inc. (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-2203435-B1 | 6, 11-BRIDGED BIARYL MACROLIDES | ENANTA PHARM INC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20180193471-A1 | ß2GPI GENE EXPRESSION-SUPPRESSING NUCLEIC ACID CONJUGATE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
| CN-104781271-B | Polynucleotides having bioreversible groups | 加利福尼亚大学董事会 | 2018-07-06 | — | — | CN | disclosed |
| EP-3334437-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | Kaleido Biosciences, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20180162893-A1 | UTILITY OF NEMATODE SMALL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-06-14 | — | — | US | disclosed |
| WO-2018106845-A1 | GLYCAN POLYMERS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| CN-108136040-A | For the multiple ligand reagent of drug delivery | 阿克丘勒斯治疗公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-104105489-B | Application of nematode micromolecules | 加州理工学院 | 2018-06-08 | — | — | CN | disclosed |
| CN-108135925-A | GLYCAN COMPOSITIONS AND USES THEREOF | 卡莱多生物科技有限公司 | 2018-06-08 | — | — | CN | disclosed |
| EP-3328439-A1 | MULTILIGAND AGENT FOR DRUG DELIVERY | Arcturus Therapeutics, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-20180147221-A1 | GLYCAN THERAPEUTIC COMPOSITIONS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180147222-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2018-05-31 | — | — | US | disclosed |
| EP-3323893-A1 | BETA2GPI GENE EXPRESSION INHIBITING NUCLEIC ACID COMPLEX | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-05-23 | — | — | EP | disclosed |
| US-9962449-B2 | MultiLigand agent for drug delivery | ARCTURUS THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9950001-B2 | Polynucleotides having bioreversible groups | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-04-24 | — | — | US | disclosed |
| CN-107771083-A | Glycan therapeutics and methods of treatment | 卡莱多生物科技有限公司 | 2018-03-06 | — | — | CN | disclosed |
| EP-3285777-A2 | GLYCAN THERAPEUTICS AND METHODS OF TREATMENT | Kaleido Biosciences, Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9901595-B2 | Glycan therapeutics for reducing blood ammonia | KALEIDO BIOSCIENCES, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9873612-B2 | Catalytic formation of carbon monoxide (CO) and hydrogen (H2) from biomass | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2018-01-23 | — | — | US | disclosed |
| WO-2018013871-A1 | GLYCAN COMPOSITIONS AND METHODS OF USE | KALEIDO BIOSCIENCES, INC. (US) | 2018-01-18 | — | — | WO | disclosed |
| US-9867882-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868754-B2 | Utility of nematode small molecules | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2018-01-16 | — | — | US | disclosed |
| WO-2018006063-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2018-01-04 | — | — | WO | disclosed |
| CN-107417745-A | The application of nematode small molecule | 加州理工学院 | 2017-12-01 | — | — | CN | disclosed |
| CN-107427528-A | Glycan therapeutics and methods related thereto | 卡莱多生物科技有限公司 | 2017-12-01 | — | — | CN | disclosed |
| US-9814777-B2 | Targeting lipids | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-11-14 | — | — | US | disclosed |
| CN-104884068-B | Polysaccharide, composition containing polysaccharide, and immune activator | 株式会社爱南自由 | 2017-11-07 | — | — | CN | disclosed |
| CN-105805426-B | Pipeline runs through device | 上海火克新材料有限公司 | 2017-10-27 | — | — | CN | disclosed |
| US-9757403-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20170246201-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-08-31 | — | — | US | disclosed |
| CN-107109405-A | Polynucleotide constructs with Bioreversible and abiotic invertibity group | 索尔斯蒂斯生物有限公司 | 2017-08-29 | — | — | CN | disclosed |
| EP-3200804-A1 | POLYSACCHARIDE AND NUCLEIC ACID FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS | Eagle Biologics, Inc. (US) | 2017-08-09 | — | — | EP | disclosed |
| CN-106999510-A | Polysaccharide and nucleic acid preparation containing viscosity reducers | 伊格尔生物制品有限公司 | 2017-08-01 | — | — | CN | disclosed |
| CN-103841827-B | Small molecule compounds for controlling plant-and insect-pathogenic nematodes | 加利福尼亚技术学院 | 2017-06-09 | — | — | CN | disclosed |
| US-20170151268-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170151269-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | HERCULES CAPITAL, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170114341-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | BRADSHAW CURT W (US) | 2017-04-27 | — | — | US | disclosed |
| EP-3156077-A1 | TARGETING LIPIDS | Arbutus Biopharma Corporation (CA) | 2017-04-19 | — | — | EP | disclosed |
| EP-3152308-A2 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | Solstice Biologics, Ltd. (IE) | 2017-04-12 | — | — | EP | disclosed |
| US-9616139-B2 | Conjugating amines | THE GENERAL HOSPITAL CORPORATION (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2231195-B1 | TARGETING LIPIDS | ARBUTUS BIOPHARMA CORP (CA) | 2017-03-29 | — | — | EP | disclosed |
| US-20170081689-A1 | Alpha (1,2) Fucosyltransferases Suitable for Use in the Production of Fucosylated Oligosaccharides | GINKGO BIOWORKS, INC. | 2017-03-23 | — | — | US | disclosed |
| EP-3141265-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| WO-2017035412-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2017023817-A1 | MULTILIGAND AGENT FOR DRUG DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| CN-103732595-B | Folate conjugates of albumin-binding entities | 默克及其合伙人公司 | 2017-02-08 | — | — | CN | disclosed |
| US-20170028074-A1 | MultiLigand Agent for Drug Delivery | ARCTURUS THERAPEUTICS, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9534008-B2 | Small molecule compounds that control plant- and insect-pathogenic nematodes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160375137-A9 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-12-29 | — | — | US | disclosed |
| US-20160376585-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | BANK OF AMERICA, N.A. | 2016-12-29 | — | — | US | disclosed |
| US-9492473-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9487551-B2 | Small molecule compounds that control mammal-pathogenic nematodes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-11-08 | — | — | US | disclosed |
| WO-2016172657-A2 | GLYCAN THERAPEUTICS AND METHODS OF TREATMENT | KALEIDO BIOSCIENCES, INC. (US) | 2016-10-27 | — | — | WO | disclosed |
| CN-106061981-A | Polynucleotide constructs having disulfide groups | 索尔斯蒂斯生物有限公司 | 2016-10-26 | — | — | CN | disclosed |
| EP-3076781-A1 | FLOWER FOAM | Spicer Designs Limited (GB) | 2016-10-12 | — | — | EP | disclosed |
| EP-3077360-A1 | Title (EN) CATALYTIC FORMATION OF CARBON MONOXIDE (CO) AND HYDROGEN (H2) FROM BIOMASS | Yeda Research and Development Co., Ltd. (IL) | 2016-10-12 | — | — | EP | disclosed |
| EP-3071235-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | Kaleido Biosciences, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9445596-B2 | Small molecule compounds for the control of nematodes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160264412-A1 | CATALYTIC FORMATION OF CARBON MONOXIDE (CO) AND HYDROGEN (H2) FROM BIOMASS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2016-09-15 | — | — | US | disclosed |
| EP-3066105-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | Solstice Biologics, Ltd. (IE) | 2016-09-14 | — | — | EP | disclosed |
| US-20160257961-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | BRADSHAW CURT W (US) | 2016-09-08 | — | — | US | disclosed |
| WO-2016122889-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20160213702-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| CN-105805426-A | Pipeline penetration device | 上海火克新材料有限公司 | 2016-07-27 | — | — | CN | disclosed |
| US-9370581-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370582-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9352048-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-3019200-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Alnylam Pharmaceuticals, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| CN-103732563-B | 18f-sugar-folic acid class | Merck & Cie (CH) | 2016-04-20 | — | — | CN | disclosed |
| WO-2016054259-A1 | POLYSACCHARIDE AND NUCLEIC ACID FORMULATIONS CONTAINING VISCOSITY-LOWERING AGENTS | Arsia Therapeutics, Inc. (US) | 2016-04-07 | — | — | WO | disclosed |
| US-9295739-B2 | Folate conjugates of albumin-binding entities | Merck & Cie (CH) | 2016-03-29 | — | — | US | disclosed |
| US-9290760-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160074522-A1 | IMMUNITY INDUCER FOR SACCHARIDE ANTIGENS | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2016-03-17 | — | — | US | disclosed |
| EP-2993182-A1 | IMMUNITY INDUCER FOR SACCHARIDE ANTIGENS | National Institute of Advanced Industrial Science and Technology (JP) | 2016-03-09 | — | — | EP | disclosed |
| WO-2016030863-A1 | COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-03 | — | — | WO | disclosed |
| US-20160053028-A1 | MEDIUM ADDITIVE FOR CELL CULTURE | DAISO CO., LTD. (JP) | 2016-02-25 | — | — | US | disclosed |
| US-20160051691-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2016-02-25 | — | — | US | disclosed |
| US-20160037741-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. | 2016-02-11 | — | — | US | disclosed |
| EP-2967052-A2 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | Boyce Thompson Institute for Plant Research Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| CN-105263324-A | Compositions and methods for modulating immunity in plants | THOMPSON BOYCE PLANT RES | 2016-01-20 | — | — | CN | disclosed |
| WO-2015188197-A2 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-12-10 | — | — | WO | disclosed |
| US-9173932-B2 | Vibrio cholerae O139 conjugate vaccines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-11-03 | — | — | US | disclosed |
| CN-104884068-A | Polysaccharide, composition containing polysaccharide, and immune activator | UNIV EHIME | 2015-09-02 | — | — | CN | disclosed |
| US-20150238516-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-08-27 | — | — | US | disclosed |
| CN-104781271-A | Polynucleotides having bioreversible groups | UNIV CALIFORNIA | 2015-07-15 | — | — | CN | disclosed |
| EP-2885313-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | The Regents of The University of California (US) | 2015-06-24 | — | — | EP | disclosed |
| WO-2015082898-A1 | FLOWER FOAM | SPICER DESIGNS LIMITED (GB) | 2015-06-11 | — | — | WO | disclosed |
| EP-2877574-A2 | ALPHA (1,2) FUCOSYLTRANSFERASES SUITABLE FOR USE IN THE PRODUCTION OF FUCOSYLATED OLIGOSACCHARIDES | Glycosyn LLC (US) | 2015-06-03 | — | — | EP | disclosed |
| WO-2015069932-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING DISULFIDE GROUPS | SOLSTICE BIOLOGICS, LTD. (IE) | 2015-05-14 | — | — | WO | disclosed |
| US-9029136-B2 | Alpha (1,2) fucosyltransferases suitable for use in the production of fucosylated oligosaccharides | Glycosyn LLC (US) | 2015-05-12 | — | — | US | disclosed |
| WO-2015063763-A1 | CATALYTIC FORMATION OF CARBON MONOXIDE (CO) AND HYDROGEN (H2) FROM BIOMASS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-05-07 | — | — | WO | disclosed |
| US-20150119444-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | BANK OF AMERICA, N.A. | 2015-04-30 | — | — | US | disclosed |
| US-20150119445-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | BANK OF AMERICA, N.A. | 2015-04-30 | — | — | US | disclosed |
| US-20150031863-A1 | CONJUGATING AMINES | THE GENERAL HOSPITAL CORPORATION (US) | 2015-01-29 | — | — | US | disclosed |
| WO-2015006740-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20150011615-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | BANK OF AMERICA, N.A. | 2015-01-08 | — | — | US | disclosed |
| US-20140364386-A1 | Small Molecule Compounds That Control Plant- and Insect-Pathogenic Nematodes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-12-11 | — | — | US | disclosed |
| CN-104151381-A | Anti-bacterial activity of 9-HYDROXY derivatives of 6, 11-bicyclolides | ENANTA PHARM INC | 2014-11-19 | — | — | CN | disclosed |
| CN-104105489-A | Application of nematode micromolecules | CALIFORNIA INSTTITUTE OF TECHNOLOGY | 2014-10-15 | — | — | CN | disclosed |
| US-20140303360-A1 | Small Molecule Compounds for the Control of Nematodes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140303102-A1 | Small Molecule Compounds that Control Mammal-Pathogenic Nematodes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-10-09 | — | — | US | disclosed |
| CN-102648280-B | Process for producing molecules containing specialized glycan structures | PROBIOGEN AG (DE) | 2014-10-08 | — | — | CN | disclosed |
| US-8852605-B2 | Vibrio cholerae O139 conjugate vaccines | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140287476-A1 | VIBRIO CHOLERAE 0139 CONJUGATE VACCINES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-09-25 | — | — | US | disclosed |
| WO-2014145380-A2 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2776382-A1 | 18F-SACCHARIDE-FOLATES | Merck & Cie (CH) | 2014-09-17 | — | — | EP | disclosed |
| US-8828956-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| CN-104004039-A | 6,11-bicyclolides: bridged biaryl macrolide derivatives | ENANTA PHARM INC | 2014-08-27 | — | — | CN | disclosed |
| US-20140234216-A1 | FOLATE CONJUGATES OF ALBUMIN-BINDING ENTITIES | Merck & Cie (CH) | 2014-08-21 | — | — | US | disclosed |
| EP-2766364-A1 | FOLATE CONJUGATES OF ALBUMIN-BINDING ENTITIES | Merck & Cie (CH) | 2014-08-20 | — | — | EP | disclosed |
| EP-2766379-A2 | SMALL MOLECULE COMPOUNDS FOR THE CONTROL OF NEMATODES | Boyce Thompson Institute For Plant Research (US) | 2014-08-20 | — | — | EP | disclosed |
| CN-102088848-B | Antibacterial activity of 6, 11-bicyclic 9-hydroxy derivatives | ENANTA PHARM INC | 2014-07-30 | — | — | CN | disclosed |
| CN-103958538-A | Small molecule compound for controlling nematodes | THOMPSON BOYCE PLANT RES | 2014-07-30 | — | — | CN | disclosed |
| US-20140193337-A1 | 18F-SACCHARIDE-FOLATES | Merck & Cie (CH) | 2014-07-10 | — | — | US | disclosed |
| US-20140187780-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140179761-A1 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-06-26 | — | — | US | disclosed |
| CN-101855219-B | 6, 11-bridged biaryl macrolides | ENANTA PHARM INC | 2014-06-25 | — | — | CN | disclosed |
| EP-2741752-A2 | THE UTILITY OF NEMATODE SMALL MOLECULES | California Institute of Technology (US) | 2014-06-18 | — | — | EP | disclosed |
| EP-2741611-A2 | SMALL MOLECULE COMPOUNDS THAT CONTROL PLANT- AND INSECT-PATHOGENIC NEMATODES | The California Institute of Technology (US) | 2014-06-18 | — | — | EP | disclosed |
| CN-103841827-A | Small molecule compounds for controlling plant-and insect-pathogenic nematodes | CALIFORNIA INST OF TECHN | 2014-06-04 | — | — | CN | disclosed |
| CN-103732563-A | 18F-saccharide-folates | Merck & Cie | 2014-04-16 | — | — | CN | disclosed |
| WO-2014031575-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-27 | — | — | WO | disclosed |
| US-20140031541-A1 | Alpha (1,2) Fucosyltransferases Suitable for Use in the Production of Fucosylated Oligosaccharides | Glycosyn LLC (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2014018596-A2 | ALPHA (1,2) FUCOSYLTRANSFERASES SUITABLE FOR USE IN THE PRODUCTION OF FUCOSYLATED OLIGOSACCHARIDES | Glycosyn LLC (US) | 2014-01-30 | — | — | WO | disclosed |
| US-8597877-B2 | Polymorphic loci that differentiate Escherichia coli O157:H7 from other strains | SEATTLE CHILDREN'S HOSPITAL (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130317080-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20130231298-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2616543-A1 | MODIFIED iRNA AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-20130178512-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130165641-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8450467-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| WO-2013009826-A9 | CONJUGATING AMINES | THE GENERAL HOSPITAL CORPORATION (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013026842-A1 | 18F-SACCHARIDE-FOLATES | Merck & Cie (CH) | 2013-02-28 | — | — | WO | disclosed |
| US-8383785-B2 | Anti-bacterial activity of 9-hydroxy derivatives of 6,11-bicyclolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| WO-2013024035-A1 | FOLATE CONJUGATES OF ALBUMIN-BINDING ENTITIES | Merck & Cie (CH) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013022997-A2 | SMALL MOLECULE COMPOUNDS THAT CONTROL PLANT- AND INSECT-PATHOGENIC NEMATODES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013022996-A2 | THE UTILITY OF NEMATODE SMALL MOLECULES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013023000-A2 | SMALL MOLECULE COMPOUNDS THAT CONTROL MAMMAL-PATHOGENIC NEMATODES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013022985-A2 | SMALL MOLECULE COMPOUNDS FOR THE CONTROL OF NEMATODES | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH (US) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013009826-A1 | CONJUGATING AMINES | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-17 | — | — | WO | disclosed |
| US-8354383-B2 | 6,11-bridged biaryl macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8273720-B2 | 6,11-bicyclolides: bridged biaryl macrolide derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| CN-102648280-A | Method for producing molecules containing specific glycan structures | VOLKER SANDIG | 2012-08-22 | — | — | CN | disclosed |
| EP-2480671-A1 | PROCESS FOR PRODUCING MOLECULES CONTAINING SPECIALIZED GLYCAN STRUCTURES | Sandig, Volker (DE) | 2012-08-01 | — | — | EP | disclosed |
| US-20120136042-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC (US) | 2012-05-31 | — | — | US | disclosed |
| US-8148112-B2 | Sugar chain containing 4-position halogenated galactose and application thereof | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2012-04-03 | — | — | US | disclosed |
| WO-2012037254-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| EP-1944377-B1 | Nucleic acid molecules specific for bacterial antigens and uses thereof | UNIV SYDNEY (AU) | 2012-03-07 | — | — | EP | disclosed |
| US-8106022-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| CN-102088848-A | Antibacterial activity of 6, 11-bicyclic 9-hydroxy derivatives | ENANTA PHARM INC | 2011-06-08 | — | — | CN | disclosed |
| CN-102006890-A | Targeting lipids | ALNYLAM PHARMACEUTICALS INC | 2011-04-06 | — | — | CN | disclosed |
| WO-2011035884-A1 | PROCESS FOR PRODUCING MOLECULES CONTAINING SPECIALIZED GLYCAN STRUCTURES | SANDIG VOLKER (DE) | 2011-03-31 | — | — | WO | disclosed |
| CN-101855219-A | 6, 11-bridged biaryl macrolides | ENANTA PHARM INC | 2010-10-06 | — | — | CN | disclosed |
| EP-2231195-A2 | TARGETING LIPIDS | Alnylam Pharmaceuticals Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2203435-A2 | 6, 11-BRIDGED BIARYL MACROLIDES | Enanta Pharmaceuticals, Inc. (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2010059958-A2 | ARTIFICIAL LECTIN MIMICS AND USES THEREOF | ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2010-05-27 | — | — | WO | disclosed |
| EP-1005537-B1 | NUCLEIC ACID MOLECULES SPECIFIC FOR BACTERIAL ANTIGENS AND USES THEREOF | UNIV SYDNEY (AU) | 2010-04-28 | — | — | EP | disclosed |
| US-7622452-B2 | C-9 alkenylidine bridged macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090285844-A1 | NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-11-19 | — | — | US | disclosed |
| WO-2009137737-A2 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6, 11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090281050-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-11-12 | — | — | US | disclosed |
| US-20090270457-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090264380-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090247608-A1 | Targeting Lipids | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090239814-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090209547-A1 | C-8 HALOGENATED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-08-20 | — | — | US | disclosed |
| WO-2009082607-A2 | TARGETING LIPIDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009075923-A2 | 6, 11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-7538092-B2 | Pharmaceutically active oligosaccharide conjugates | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2009-05-26 | — | — | US | disclosed |
| WO-2009064953-A1 | USE OF BRIDGED MACROLIDES OR TYLOSIN DERIVATIVES IN TREATING INFLAMMATORY BOWEL DISEASES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131343-A1 | USE OF BRIDGED MACROLIDES OR TYLOSIN DERIVATIVES IN TREATING INFLAMMATORY BOWEL DISEASES | ENANTA PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| CN-101429215-A | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | MITSUI CHEMICALS INC (JP) | 2009-05-13 | — | — | CN | disclosed |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-7527797-B1 | Capsular polysaccharide of Vibrio cholerae O139 covalently bound with an adipic acid dihydrazide linker to a recombinant diphtheria toxin carrier protein eliciting serum vibriocidal antibodies; conjugated with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC), | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-05-05 | — | — | US | disclosed |
| EP-0876150-B2 | NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA | UNIV IOWA RES FOUND (US) | 2009-04-29 | — | — | EP | disclosed |
| US-7510717-B2 | Non-toxic mutants of pathogenic gram-negative bacteria | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2009-03-31 | — | — | US | disclosed |
| WO-2009039177-A1 | 6, 11-BICYCLOIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2009-03-26 | — | — | WO | disclosed |
| US-20090075915-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2009026527-A1 | NOVEL MACROLACTAM COMPOUNDS | NOVOBIOTIC PHARMACEUTICALS LLC (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090018327-A1 | SUGAR CHAIN CONTAINING 4-POSITION HALOGENATED GALACTOSE AND APPLICATION THEREOF | NATIONAL UNIVERSITY CORP. HOKKAIDO UNIVERSITY (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1476197-B1 | SYNTHESIS OF LIPOPOLYSACCHARIDE-PROTEIN CONJUGATE VACCINES VIA THE LIPID A REGION FOLLOWING REMOVAL OF THE GLYCOSIDIC PHOSPHATE RESIDUE | CA NAT RESEARCH COUNCIL (CA) | 2009-01-07 | — | — | EP | disclosed |
| EP-1549350-B1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | FRESENIUS KABI DE GMBH (DE) | 2008-09-24 | — | — | EP | disclosed |
| EP-1944377-A2 | Nucleic acid molecules specific for bacterial antigens and uses thereof | THE UNIVERSITY OF SYDNEY (AU) | 2008-07-16 | — | — | EP | disclosed |
| EP-1178051-B1 | PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE | MITSUI CHEMICALS INC (JP) | 2008-05-28 | — | — | EP | disclosed |
| WO-2008061189-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080119418-A1 | C-9 ALKENYLIDINE BRIDGED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080102458-A1 | Polymorphic loci that differentiate escherichia coli 0157:H7 from other strains | CHILDREN'S HOSPITAL AND REGIONAL MEDICAL CENTER (US) | 2008-05-01 | — | — | US | disclosed |
| US-7364739-B2 | Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of Haemophilus influenzae infections | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2008-04-29 | — | — | US | disclosed |
| US-20070166315-A1 | VIBRIO CHOLERAE O139 CONJUGATE VACCINES | The Government of the United States of America as represented by the Secretary of the | 2007-07-19 | — | — | US | disclosed |
| US-7226588-B2 | Non-toxic mutants of pathogenic gram-negative bacteria | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2007-06-05 | — | — | US | disclosed |
| US-20070104736-A1 | NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA | UNIVERSITY OF IOWA RESEARCH FOUNDATION, A IOWA CORPORATION | 2007-05-10 | — | — | US | disclosed |
| EP-1313771-B1 | HAEMOPHILUS INFLUENZAE LIPOPOLYSACCHARIDE INNER-CORE OLIGOSACCHARIDE EPITOPES AS VACCINES FOR THE PREVENTION OF HAEMOPHILUS INFLUENZAE INFECTIONS | AVENTIS PASTEUR (CA) | 2007-03-21 | — | — | EP | disclosed |
| US-20070048331-A1 | Non-toxic mutants of pathogenic gram-negative bacteria | UNIV. OF IOWA RESEARCH FOUNDATION | 2007-03-01 | — | — | US | disclosed |
| US-7148005-B2 | Nucleic acid-based methods of detecting bacterial o-antigens | THE UNIVERSITY OF SYDNEY (AU) | 2006-12-12 | — | — | US | disclosed |
| US-7125661-B1 | Sequences for the detection of Escherichia coli | THE UNIVERSITY OF SYDNEY (AU) | 2006-10-24 | — | — | US | disclosed |
| US-20060100163-A1 | Pharmaceutically active oligosaccharide conjugates | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
| US-20060094869-A1 | Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-7038039-B2 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | MITSUI CHEMICALS, INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| US-7005129-B1 | Non-toxic mutants of pathogenic gram-negative bacteria | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2006-02-28 | — | — | US | disclosed |
| US-20050267169-A1 | Watersoluble prodrugs of propofol | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2005-12-01 | — | — | US | disclosed |
| EP-0876150-B1 | NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA | UNIV IOWA RES FOUND (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1080102-A4 | ANTIGENS AND THEIR DETECTION | UNIV SYDNEY (AU) | 2005-07-20 | — | — | EP | disclosed |
| EP-1554242-A1 | WATERSOLUBLE PRODRUGS OF PROPOFOL | Fresenius Kabi Deutschland GmbH (DE) | 2005-07-20 | — | — | EP | disclosed |
| US-20050153057-A1 | Haemophilus influenzae lipopolysaccharide inner-core oligosaccharide epitopes as vaccines for the prevention of haemophilus influenzae infections | NATIONAL RESEARCH COUNCIL OF CANADA, A CROWN CORPORATION INCORPORATED AS A COMPANY UNDER THE NATIONAL RESEARCH COUNCIL ACT BY THE PARLIAMENT OF CANADA (CA) | 2005-07-14 | — | — | US | disclosed |
| US-20050147624-A1 | Synthesis of lipopolysaccharide-protein conjugate vaccines via the lipid a region following removal of the glycosidic phosphate residue | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2005-07-07 | — | — | US | disclosed |
| EP-1549350-A1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | Fresenius Kabi Deutschland GmbH (DE) | 2005-07-06 | — | — | EP | disclosed |
| EP-1005537-A4 | NUCLEIC ACID MOLECULES SPECIFIC FOR BACTERIAL ANTIGENS AND USES THEREOF | UNIV SYDNEY (AU) | 2005-06-15 | — | — | EP | disclosed |
| US-6887483-B2 | Non-toxic mutants of pathogenic gram-negative bacteria | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2005-05-03 | — | — | US | disclosed |
| US-20050048076-A1 | NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA | SCHWEGMAN, LINDBERG, WOESSNER AND KLUTH, P.A. | 2005-03-03 | — | — | US | disclosed |
| US-20050032852-A1 | Prodrugs of cox-2 inhibitors | CARTER JEFFERY S (US) | 2005-02-10 | — | — | US | disclosed |
| EP-1476197-A2 | SYNTHESIS OF LIPOPOLYSACCHARIDE-PROTEIN CONJUGATE VACCINES VIA THE LIPID A REGION FOLLOWING REMOVAL OF THE GLYCOSIDIC PHOSPHATE RESIDUE | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2004-11-17 | — | — | EP | disclosed |
| US-6809111-B2 | ANTIINFLAMMATORY AGENTS; ANALGESICS | PHARMACIA CORPORATION | 2004-10-26 | — | — | US | disclosed |
| WO-2002016440-A9 | HAEMOPHILUS INFLUENZAE LIPOPOLYSACCHARIDE INNER-CORE OLIGOSACCHARIDE EPITOPES AS VACCINES FOR THE PREVENTION OF HAEMOPHILUS INFLUENZAE INFECTIONS | AVENTIS PASTEUR (CA) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004032971-A1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004033424-A1 | WATERSOLUBLE PRODRUGS OF PROPOFOL | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2004-04-22 | — | — | WO | disclosed |
| EP-1379513-A1 | PRODRUGS OF COX-2 INHIBITORS | Pharmacia Corporation (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20040002522-A1 | Prodrugs of COX-2 inhibitors | PHARMACIA CORPORATION | 2004-01-01 | — | — | US | disclosed |
| US-6613790-B2 | For therapy of cyclooxygenase-2 mediated disease | PHARMACIA CORPORATION | 2003-09-02 | — | — | US | disclosed |
| WO-2003070282-A2 | SYNTHESIS OF LIPOPOLYSACCHARIDE-PROTEIN CONJUGATE VACCINES VIA THE LIPID A REGION FOLLOWING REMOVAL OF THE GLYCOSIDIC PHOSPHATE RESIDUE | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2003-08-28 | — | — | WO | disclosed |
| EP-1313771-A2 | HAEMOPHILUS INFLUENZAE LIPOPOLYSACCHARIDE INNER-CORE OLIGOSACCHARIDE EPITOPES AS VACCINES FOR THE PREVENTION OF HAEMOPHILUS INFLUENZAE INFECTIONS | Aventis Pasteur Limited (CA) | 2003-05-28 | — | — | EP | disclosed |
| US-20030055012-A1 | Prodrugs of COX-2 inhibitors | PHARMACIA CORPORATION | 2003-03-20 | — | — | US | disclosed |
| US-20030018349-A1 | NUCLEIC ACID MOLECULES SPECIFIC FOR BACTERIAL ANTIGENS AND USES THEREOF | SYDNEY UNIVERSITY OF THE (AU) | 2003-01-23 | — | — | US | disclosed |
| US-20020193314-A1 | Process for selectively producing 1-phosphorylated sugar derivative anomer and process for producing nucleoside | MITSUI CHEMICALS, INC. (JP) | 2002-12-19 | — | — | US | disclosed |
| CN-1378598-A | Evolution and use of enzymes for combinathorial and medicinal chemistry | MAXYGEN INC (US) | 2002-11-06 | — | — | CN | disclosed |
| WO-2002083655-A1 | PRODRUGS OF COX-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |
| US-20020150902-A1 | Polymorphic loci that differentiate escherichia coli 0157:H7 from other strains | CHILDREN'S HOSPITAL AND REGIONAL MEDICAL CENTER | 2002-10-17 | — | — | US | disclosed |
| EP-1147196-A4 | POLYMORPHIC LOCI THAT DIFFERENTIATE ESCHERICHIA COLI 0157:H7 FROM OTHER STRAINS | CHILDRENS HOSP MEDICAL CENTER (US) | 2002-10-16 | — | — | EP | disclosed |
| CN-1372564-A | Process for selectively preparing anomers of 1-phosphorylated sugar derivatives and process for preparing nucleosides | MITSUI CHEMICALS INC (JP) | 2002-10-02 | — | — | CN | disclosed |
| EP-1208209-A1 | EVOLUTION AND USE OF ENZYMES FOR COMBINATION AND MEDICINAL CHEMISTRY | Maxygen, Inc. (US) | 2002-05-29 | — | — | EP | disclosed |
| EP-0682527-B1 | CARBOHYDRATE-BASED DIAGNOSTIC REAGENT FOR TRICHINOSIS | UNIV COLORADO STATE RES FOUND (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2002020059-A2 | VIBRIO CHOLERAE O139 CONJUGATE VACCINES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002016440-A2 | HAEMOPHILUS INFLUENZAE LIPOPOLYSACCHARIDE INNER-CORE OLIGOSACCHARIDE EPITOPES AS VACCINES FOR THE PREVENTION OF HAEMOPHILUS INFLUENZAE INFECTIONS | AVENTIS PASTEUR LIMITED (CA) | 2002-02-28 | — | — | WO | disclosed |
| EP-1178051-A2 | PROCESS FOR SELECTIVELY PRODUCING 1-PHOSPHORYLATED SUGAR DERIVATIVE ANOMER AND PROCESS FOR PRODUCING NUCLEOSIDE | Mitsui Chemicals, Inc. (JP) | 2002-02-06 | — | — | EP | disclosed |
| CN-1333831-A | Polymorphic sites to distinguish E.coli 0157: H7 from other strains | CHILDREN S HOSPITAL AND REGION (US) | 2002-01-30 | — | — | CN | disclosed |
| EP-1147196-A1 | POLYMORPHIC LOCI THAT DIFFERENTIATE ESCHERICHIA COLI 0157:H7 FROM OTHER STRAINS | CHILDREN'S HOSPITAL AND MEDICAL CENTER (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1080102-A1 | ANTIGENS AND THEIR DETECTION | THE UNIVERSITY OF SYDNEY (AU) | 2001-03-07 | — | — | EP | disclosed |
| WO-2001012817-A1 | EVOLUTION AND USE OF ENZYMES FOR COMBINATHORIAL AND MEDICINAL CHEMISTRY | MAXYGEN, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-2000034484-A1 | POLYMORPHIC LOCI THAT DIFFERENTIATE ESCHERICHIA COLI 0157:H7 FROM OTHER STRAINS | CHILDREN'S HOSPITAL AND REGIONAL MEDICAL CENTER (US) | 2000-06-15 | — | — | WO | disclosed |
| EP-1005537-A1 | NUCLEIC ACID MOLECULES SPECIFIC FOR BACTERIAL ANTIGENS AND USES THEREOF | THE UNIVERSITY OF SYDNEY (AU) | 2000-06-07 | — | — | EP | disclosed |
| WO-1999061458-A1 | ANTIGENS AND THEIR DETECTION | THE UNIVERSITY OF SYDNEY (AU) | 1999-12-02 | — | — | WO | disclosed |
| WO-1998053851-A1 | LAFT MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998050531-A1 | NUCLEIC ACID MOLECULES SPECIFIC FOR BACTERIAL ANTIGENS AND USES THEREOF | THE UNIVERSITY OF SYDNEY (AU) | 1998-11-12 | — | — | WO | disclosed |
| EP-0876150-A1 | NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1998-11-11 | — | — | EP | disclosed |
| US-5707817-A | TYVELOSE JOINED TO GLYCOSIDES LINKAGES | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1998-01-13 | — | — | US | disclosed |
| US-5686256-A | TYVELOSE-CONTAINING DISACCHARIDE OR OLIGOSACCHARIDE BINDS WITH ANTIBODY TO FORM COMPLEX | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1997-11-11 | — | — | US | disclosed |
| WO-1997019688-A9 | NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA | — | 1997-09-18 | — | — | WO | disclosed |
| WO-1997019688-A1 | NON-TOXIC MUTANTS OF PATHOGENIC GRAM-NEGATIVE BACTERIA | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 1997-06-05 | — | — | WO | disclosed |
| EP-0682527-A4 | CARBOHYDRATE-BASED VACCINE AND DIAGNOSTIC REAGENT FOR TRICHINOSIS. | UNIV COLORADO STATE RES FOUND (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996030044-A1 | CARBOHYDRATE-BASED VACCINE AND DIAGNOSTIC REAGENT FOR TRICHINOSIS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1996-10-03 | — | — | WO | disclosed |
| US-5541075-A | DISACCHARIDES, OLIGOSACCHARIDES | HESKA CORPORATION (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0682527-A1 | CARBOHYDRATE-BASED VACCINE AND DIAGNOSTIC REAGENT FOR TRICHINOSIS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-11-22 | — | — | EP | disclosed |
| WO-1994017824-A1 | CARBOHYDRATE-BASED VACCINE AND DIAGNOSTIC REAGENT FOR TRICHINOSIS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1994-08-18 | — | — | WO | disclosed |
| US-5057598-A | Monoclonal antibodies reactive with endotoxin core | CENTOCOR, INC. (US) | 1991-10-15 | — | — | US | disclosed |
| EP-0151128-B1 | MONOCLONAL ANTIBODIES REACTIVE WITH ENDOTOXIN CORE | VELOS GROUP (US) | 1991-07-03 | — | — | EP | disclosed |
| EP-0286099-A2 | Monoclonal antibodies reactive with endotoxin core | VELOS GROUP (US) | 1988-10-12 | — | — | EP | disclosed |
| EP-0151128-A4 | MONOCLONAL ANTIBODIES REACTIVE WITH ENDOTOXIN CORE. | VELOS GROUP (US) | 1985-09-09 | — | — | EP | disclosed |
| EP-0151128-A1 | MONOCLONAL ANTIBODIES REACTIVE WITH ENDOTOXIN CORE. | VELOS GROUP (US) | 1985-08-14 | — | — | EP | disclosed |
| WO-1984004458-A1 | MONOCLONAL ANTIBODIES REACTIVE WITH ENDOTOXIN CORE | POLLACK MATTHEW | 1984-11-22 | — | — | WO | disclosed |
| WO-1984004458-A1 | MONOCLONAL ANTIBODIES REACTIVE WITH ENDOTOXIN CORE | POLLACK MATTHEW | 1984-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (50 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274753-B2 | Compositions and methods for targeted RNA delivery | PCSK9, LDLR, PCSK7 | AKR1B1 1898/4885GAPDH 553/4885 |
| US-20140193337-A1 | 18F-SACCHARIDE-FOLATES | FOLR1, FOLR2, FOLH1 | AKR1B1 965/4885GAPDH 701/4885 |
| US-11471479-B2 | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents | RNGTT, SNRPA, SNRNP200 | AKR1B1 4163/4885GAPDH 2912/4885 |
| US-20160376585-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | AKR1B1 1277/4885GAPDH 2316/4885 |
| US-11772063-B2 | Method and device for producing saccharides and saccharide arrays | MGAM, SORD, FUT5 | AKR1B1 2127/4885GAPDH 640/4885 |
| US-20030055012-A1 | Prodrugs of COX-2 inhibitors | PTGS2, PTGS1, PTGES2 | AKR1B1 96/4885GAPDH 232/4885 |
| US-20090075915-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | CYP2B6, ABCB11, CYP2D6 | AKR1B1 259/4885GAPDH 2022/4885 |
| US-10808246-B2 | Oligonucleotide-ligand conjugates and process for their preparation | RTCB, IGF2BP2, SNRPE | AKR1B1 1653/4885GAPDH 1064/4885 |
| US-20090247608-A1 | Targeting Lipids | LY96, ABHD10, APOB | AKR1B1 3503/4885GAPDH 2247/4885 |
| US-20090018327-A1 | SUGAR CHAIN CONTAINING 4-POSITION HALOGENATED GALACTOSE AND APPLICATION THEREOF | GALK1, GALE, UGGT1 | AKR1B1 472/4885GAPDH 386/4885 |
| US-20140234216-A1 | FOLATE CONJUGATES OF ALBUMIN-BINDING ENTITIES | ALB, FOLR1, FOLR2 | AKR1B1 932/4885GAPDH 2026/4885 |
| US-20240100169-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | PCSK9, LDLR, PCSK7 | AKR1B1 1898/4885GAPDH 553/4885 |
| US-20220111034-A1 | VIRUS COMPOSITIONS | SIGLEC7, SIGLEC9, NEU3 | AKR1B1 3682/4885GAPDH 1529/4885 |
| US-20220127605-A1 | NUCLEIC ACID CONJUGATE | NSUN3, NSUN2, RNASEH1 | AKR1B1 1669/4885GAPDH 1107/4885 |
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | AKR1B1 2243/4885GAPDH 3604/4885 |
| US-20250236636-A1 | COMPOSITIONS AND METHODS FOR CAPPING RNAS | RNGTT, NSUN2, RNMT | AKR1B1 4436/4885GAPDH 1604/4885 |
| US-20090270457-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | CYP2B6, ABCB11, CYP2D6 | AKR1B1 259/4885GAPDH 2022/4885 |
| US-10745700-B2 | Nucleic acid conjugate | SLC29A1, NSUN2, H1-2 | AKR1B1 1121/4885GAPDH 1010/4885 |
| US-20240189797-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE BINDING DOMAIN CONTAINING MOLECULES | CACYBP, MGAM, MASP2 | AKR1B1 2943/4885GAPDH 3747/4885 |
| US-20180326070-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | LPXN, ZYX, OSTC | AKR1B1 2156/4885GAPDH 1830/4885 |
| US-20130178512-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | LPXN, ZYX, OSTC | AKR1B1 2156/4885GAPDH 1830/4885 |
| US-20130165641-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | AKR1B1 198/4885GAPDH 1524/4885 |
| US-20130231298-A1 | ANTI-BACTERIAL ACTIVITY OF 9-HYDROXY DERIVATIVES OF 6,11-BICYCLOLIDES | CYP8B1, SI, CYP51A1 | AKR1B1 890/4885GAPDH 1196/4885 |
| US-20250228953-A1 | INTRACELLULAR TARGETING OF OLIGONUCLEOTIDES | MAN1B1, RNASE1, ERAP1 | AKR1B1 3229/4885GAPDH 2276/4885 |
| US-20190184018-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | SLC2A2, SLC2A8, SLC2A1 | AKR1B1 1385/4885GAPDH 1329/4885 |
| US-20180193471-A1 | ß2GPI GENE EXPRESSION-SUPPRESSING NUCLEIC ACID CONJUGATE | GALNT2, ST6GAL1, SLC17A5 | AKR1B1 1235/4885GAPDH 616/4885 |
| US-20060094869-A1 | Selective process for producing an anomer of a 1-phosphorylated saccharide derivative and process for producing a nucleoside | PNP, MTAP, GALE | AKR1B1 1104/4885GAPDH 608/4885 |
| US-11019776-B2 | Compositions and methods for modulating immunity in plants | SLC11A2, IFNG, STING1 | AKR1B1 3385/4885GAPDH 1227/4885 |
| US-20050267169-A1 | Watersoluble prodrugs of propofol | PIGS, OPRL1, PAM | AKR1B1 1833/4885GAPDH 2000/4885 |
| US-20220348914-A1 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | IGF2R, IRS1, INSR | AKR1B1 1277/4885GAPDH 2316/4885 |
| US-20230024046-A1 | UTILITY OF NEMATODE SMALL MOLECULES | NOD2, MYD88, NOD1 | AKR1B1 2012/4885GAPDH 4671/4885 |
| US-12180246-B2 | Utility of nematode small molecules | NOD2, MYD88, NOD1 | AKR1B1 2012/4885GAPDH 4671/4885 |
| US-20160037741-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | SLC11A2, IFNG, STING1 | AKR1B1 3385/4885GAPDH 1227/4885 |
| US-20240190913-A1 | SEPARATION MEDIA AND PURIFICATION METHODS FOR CARBOHYDRATE CONTAINING MOLECULES USING THE SAME | MGAM, MASP2, MGAM2 | AKR1B1 2538/4885GAPDH 2583/4885 |
| US-20090131343-A1 | USE OF BRIDGED MACROLIDES OR TYLOSIN DERIVATIVES IN TREATING INFLAMMATORY BOWEL DISEASES | TNF, SLC10A2, TMSB4X | AKR1B1 1078/4885GAPDH 3045/4885 |
| US-20150119445-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | LPXN, ZYX, OSTC | AKR1B1 2192/4885GAPDH 2041/4885 |
| US-20190053451-A1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY IN PLANTS | SLC11A2, IFNG, STING1 | AKR1B1 3385/4885GAPDH 1227/4885 |
| US-20180303864-A1 | POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS | RNASE1, NCL, LNPEP | AKR1B1 4538/4885GAPDH 2630/4885 |
| US-20160053028-A1 | MEDIUM ADDITIVE FOR CELL CULTURE | NEFM, CD44, ALG1 | AKR1B1 4652/4885GAPDH 1410/4885 |
| US-20240131166-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | PCSK9, LDLR, PCSK7 | AKR1B1 1898/4885GAPDH 553/4885 |
| US-10479813-B2 | Utility of nematode small molecules | NOD2, MYD88, NOD1 | AKR1B1 2012/4885GAPDH 4671/4885 |
| US-10322195-B2 | 18F-saccharide-folates | FOLR1, FOLR2, FOLH1 | AKR1B1 931/4885GAPDH 710/4885 |
| US-20160264412-A1 | CATALYTIC FORMATION OF CARBON MONOXIDE (CO) AND HYDROGEN (H2) FROM BIOMASS | HAO2, HPD, HAAO | AKR1B1 3893/4885GAPDH 228/4885 |
| US-20240018177-A1 | UTILITY OF NEMATODE SMALL MOLECULES | NOD2, MYD88, NOD1 | AKR1B1 2012/4885GAPDH 4671/4885 |
| US-20090209547-A1 | C-8 HALOGENATED MACROLIDES | CYP2C8, CCR8, CXCL8 | AKR1B1 929/4885GAPDH 4168/4885 |
| US-12173288-B2 | Oligonucleotide-ligand conjugates and process for their preparation | IGF2R, IRS1, INSR | AKR1B1 1277/4885GAPDH 2316/4885 |
| US-20140179761-A1 | TARGETING LIPIDS | LY96, ABHD10, APOB | AKR1B1 3572/4885GAPDH 2291/4885 |
| US-12569570-B2 | Compositions and methods for targeted RNA delivery | LDLR, ASGR1, PCSK9 | AKR1B1 544/4885GAPDH 1716/4885 |
| US-20200297853-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | SLC2A2, SLC2A8, SLC2A1 | AKR1B1 1385/4885GAPDH 1329/4885 |
| US-11666653-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | HAVCR2, B3GAT3, CSGALNACT1 | AKR1B1 406/4885GAPDH 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.